equity Morningstar uses to value other global medical device companies such as Medtronic MDT, St. Jude STJ and Boston Scientific BSX . The lower cost of equity increases our fair value estimate from USD 40 to USD 45. In addition to the impact
companies such as Medtronic MDT, St. Jude STJ and Boston Scientific BSX . In fiscal 2013, we expect innovation and continued ..... device companies such as Medtronic, St Jude and Boston Scientific . In fiscal 2013, we expect innovation and continued
By Robert Honeywill : In Part I of "Johnson & Johnson: At The Crossroads", it was determined that a dividend growth rate of 8.2% was sustainable for at least the next 15 years even if net income growth rate remained around the projected 6%. In Part II , it was determined that Johnson & Johnson ( ...
Boston Scientific ( BSX -1% ) slides in spite of reporting positive results earlier today from a pre-specified analysis of the first 60 patients enrolled
Boston Scientific ( BSX +0.4% ) says five-year data from its Asthma Intervention Research 2 clinical trial presented today demonstrated that the
stent was a disappointment. The firm received domestic regulatory approval for its own stent in 2008, long after Boston Scientific BSX and Johnson & Johnson JNJ established footprints in that market. Further exacerbating the situation, Medtronic's
By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday May 17. 17 Things To Watch In The Week Ahead: Campbell Soup ( CPB ), Best Buy ( BBY ), AutoZone ( AZO ), Home Depot ( HD ), TJX Companies ( TJX ), NetApp ( NTAP ), Target ( TGT ),
By Robert Honeywill : In Part I of "Johnson & Johnson: At The Crossroads", consideration was given to whether a dividend growth rate of 8.2% was sustainable if net income growth rate remained around the projected 6%. It was determined that this gap between dividend and net income growth rates was
By Trefis : Boston Scientific 's ( BSX ) stock rallied over 5% on Thursday after the medical device ..... fibrillation patients. This could come as a major boost for Boston Scientific , which has been grappling with declining sales and market
By Robert Honeywill : Part I of this series on Johnson & Johnson ( JNJ ) mainly addressed the sustainability of an increasing dividend payout ratio. If current projections for dividend growth rate remained at 8.2% per year and those for net income growth rate at ~6% per year, it was shown to be ...